The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma

作     者：Shuai Kang Xue Bai Shujie Chen Yang Song Li Liu Shuai Kang;Xue Bai;Shujie Chen;Yang Song;Li Liu

作者机构：Hepatology Unit and Department of Infectious DiseasesNanfang HospitalSouthern Medical UniversityGuangzhouChina Department of Radiation OncologyNanfang HospitalSouthern Medical UniversityGuangzhouChina 

出 版 物：《Journal of Interventional Medicine》 (介入医学杂志（英文）)

年 卷 期：2019年第2卷第2期

页      面：47-51页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Hepatocellular carcinoma Combinational therapy Immunotherapy Immune checkpoint 

摘      要：The treatment choices available for hepatocellular carcinoma(HCC)are limited and *** improvements in our understanding of the mechanism involving immune checkpoints,including programmed cell death protein 1(PD1),programmed death-ligand 1(PD-L1),and cytotoxic T-lymphocyte-associated protein 4(CTLA-4),and also progress in the development of medicines make immunotherapy a promising approach to the treatment of numerous cancers,especially ***,around 40%of patients still suffer from a progressive disease when treated with a *** clinical trials applying a combination therapy including immune checkpoint inhibitors have demonstrated the durable antitumor activity of these approaches in HCC *** clinical trials were done with the intent of evaluating the safety of these combination therapies,as well as whether they help improve the overall survival of *** study reviewed the recent progress in the use of combination therapies including immunotherapy in treating patients with HCC.